Glioma test kit GLIOCAN™

oncologyfor precision medicinefor BRAF mutations

Primary central nervous system (CNS) tumors are a group of tumor types originating from the brain or spinal cord tissue, and can be differentiated from metastatic brain tumors that spread to the brain from a tumor developed in another part of the body. Although certain genetic syndromes may increase the risk of developing CNS tumors, the causes of most adult primary CNS tumors are still unknown. CNS tumors can be benign or malignant. Current standard treatment options consist of surgery, radiation therapy and chemotherapy. Recent genome-wide studies of malignant CNS tumors have unveiled molecular biomarkers that may influence clinical treatment decision-making – some of which have been incorporated by the World Health Organization (WHO) into Classification of Tumors of the Central Nervous System in 2016. These tumors were classified based on both histological appearance and molecular parameters. Targets 12 key molecular biomarkers in glioma Comprehensive testing of genetic alterations such as diagnostic, prognostic or predictive biomarkers in glioma, including 1p/19q co-deletion, mutations in ATRX, BRAF, IDH1, IDH2, TERT and TP53 genes Facilitates tumor classification and grading Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers Optional MGMT promoter methylation test WHO IS IT FOR Newly diagnosed glioma patients seeking precision medicine  SAMPLE TYPES Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy